Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

Jorge Echeverri1 Global Medical Affairs, Baxter Healthcare Corporation, Deerfield, IL, USAView further author information

Rui Martins2 University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;3 Health Economics; Global Market Access Solutions, Saint Prex, SwitzerlandCorrespondence[email protected]
View further author information

Kai Harenski4 Global Medical Affairs, Baxter Deutschland GmbH, Unterschleissheim, GermanyView further author information

J Patrick Kampf5 Biomarker Research, Astute Medical Inc. (a bioMerieux Company), San Diego, CA, USAView further author information

Paul McPherson5 Biomarker Research, Astute Medical Inc. (a bioMerieux Company), San Diego, CA, USAView further author information

Julien Textoris6 Medical Affairs; bioMerieux, SA, Lyon, France;7 Service d´Anesthésie et de Réanimation; Hospices Civils de Lyon, Lyon, FranceView further author information

Jay L Koyner8 Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USAView further author information

show all

Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date